section name header

Pronunciation

fi-dax-oh-MYE-sin

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: macrolides

Indications

REMS


Action

  • Bactericidal action mostly against clostridia; inhibits RNA synthesis.
  • Acts locally in the GI tract to eliminate Clostridioides difficile.
Therapeutic effects:
  • Elimination of diarrhea caused by Clostridioides difficile.

Pharmacokinetics

Absorption: Minimal systemic absorption.

Distribution: Stays primarily in the GI tract.

Metabolism/Excretion: Mostly transformed via hydrolysis in the GI tract to OP-1118, its active metabolite. Eliminated mostly (>92%) in feces: <1% excreted in urine.

Half-Life: Fidaxomicin: 11.7 hr; OP-1118: 11.2 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
POunknownunknownunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Dificid